References

1. Montinari, M., Minelli, S. & De Caterina, R. (2018). The first 3500 years of aspirin history from its roots – a concise summary. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2018.10.008
2. Bjarnason, I. et al. (2018) Mechanisms of damage to the gastrointestinal tract form nonsteroidal anti-inflammatory drugs. Gastroenterology. 154: 500-514.
3. Vonkeman, H., van der Laar, M. (2010). Nonsteroidal anti-inflammatory drugs: Adverse effects and their prevention. Seminars in Arthritis and Rheumatology. 39: 294-312
4. Rang, H. et al. (2016). Rang and Dale’s Pharmacology. (8^th edition). Churchill Livingstone.
5. McNeil, J. et al. (2018). Effect of aspirin on all-cause mortality in the healthy elderly. New England Journal of Medicine. 379: 1519-1528.
6. Varga, Z. et al. (2017). Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus. 9(4): e1144.
7. Sala, A. et al. (2018). Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade. Biochemical Pharmacology. 158: 161-173.
8. Ridderikhof, M. et al. (2018). Acetaminophen or nonsteroidal anti-inflammatory drugs in acute musculoskeletal trauma: a multicentre, double blind, randomized, clinical trial. Annals of Emergency Medicine. 71(3): 357-368.
9. Enthoven, W. et al. (2016). Nonsteroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database for Systematic Reviews. 2016(2): CD012087.
10. Hung, K. et al. (2018). Oral paracetamol and/or ibuprofen for treating pain after soft tissue injuries: single centre double-blind, randomised controlled clinical trial. PLoS ONE. 13(2): e0192043.
11. Marjoribanks, J. et al. (2015). Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews. 2015(7): CD001751.
12. Strawson, J. (2018). Nonsteroidal anti-inflammatory drugs and cancer pain. Current Opinion in Supportive and Palliative Care. 12(2): 102-107.
13. Wiffen, P. et al. (2017). Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews. 2017(7): CD012637.
14. Derry, S. et al. (2017). Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database of Systematic Reviews. 2017(7): CD012638.
15. Stroke Foundation of New Zealand and New Zealand Guidelines Group. (2010). Clinical Guidelines for Stroke Management 2010. Wellington: Stroke Foundation of New Zealand.
16. Hankey, G. (2016). The benefits of aspirin in early secondary stroke prevention. The Lancet. 388(10042): 312-314.
17. Gargiulo, G. et al. (2016). A critical appraisal of aspirin in secondary prevention. Circulation. 134(23): 1881-1906.
18. Ridker, P. (2018). Should aspirin be used for primary prevention in the post-statin era? The New England Journal of Medicine. 379: 16.
19. Zheng, S. & Roddick, A. (2019). Association of aspirin use for primary prevention with cardiovascular and bleeding events: a systematic review and meta-analysis. JAMA.321(3): 227-287.
20. Gaziano, J. (2019). Aspirin for primary prevention: Clinical considerations in 2019. JAMA. 321(3): 253-255.
21. United States Preventive Services Task Force. (2017). Final recommendation statement: aspirin use to prevent cardiovascular disease and colorectal cancer. Accessed November 2018. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer
22. Ministry of Health. (2018). Cardiovascular disease risk assessment and management for primary care. Wellington: Ministry of Health.
23. National Vascular Disease Prevention Alliance. (2012). Guidelines for the management of absolute cardiovascular risk. National Stroke Foundation. Accessed March 2019. https://www.heartfoundation.org.au/images/uploads/publications/Absolute-CVD-Risk-Full-Guidelines.pdf
24. Piepoli, M. et al. (2016). Sixth joint task force of the European Society of Cardiology and other Societies on cardiovascular prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation. European Heart Journal. 37(29): 2315-2381.
25. Patrignani, P. & Patrono, C. (2016). Aspirin and cancer. Journal of the American College of Cardiology. 68(9): 967-976.
26. Barnard, M. et al. (2018). Association of analgesic use with risk of ovarian cancer in the Nurses’ Health Studies. JAMA Oncology. Published online October 04, 2018. doi:10.1001/jamaoncol.2018.4149.
27. Verdoodt, F., Kjaer, S. & Friis, S. (2017). Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: summary of epidemiologic evidence of cancer risk and prognosis. Maturitas. 100: 1-7.
28. Veronese, N. et al. (2017). Low dose aspirin use and cognitive function in older age: a systematic review and meta-analysis. Journal of the American Geriatric Society. 65: 1763-1768.
29. Chang, C. et al. (2016). Mean daily dosage of aspirin and the risk of incident Alzheimer’s dementia in patients with type 2 diabetes mellitus: a nationwide retrospective cohort study in Taiwan. Journal of Diabetes Research. Article ID 9027484, 8 pages
30. Imbimbo, B. (2009). An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer’s disease. Expert Opinion in Investigative Drugs. 18(8): 1147-68.
31. Chandra, S. et al. (2018) Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of Alzheimer’s disease via PPAR⍺. Journal of Neuroscience. 0054-18. DOI: 10.1523/JNEUROSCI.0054-18.2018
32. De Oliveira Carvalho, P., et al. (2016). Oral aspirin for treating venous leg ulcers. Cochrane Database of Systematic Reviews. 2016(2): CD009432.
33. Tilbrook, H., et al. (2018). AVURT: aspirin versus placebo for the treatment of venous leg ulcers – a phase II pilot randomised controlled trial. Health Technology Assessment. 22(55).
34. Grosser, T., Ricciotti, E. & Fitzgerald, G. (2017). The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends in Pharmacological Sciences. 38(8): 733-748.
35. Sostres, C., Gargallo, C. & Lanas, A. (2013). Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Research and Therapy. 15(suppl. 3): S3.
36. Katzung, B., Masters, S. & Trevor, A. (2012). Basic and clinical pharmacology. (12^th edition). New York: McGraw Hill.
37. Davis, A. & Robson, J. 2016). The dangers of NSAIDs: look both ways. British Journal of General Practice.  66(645): 172-173.
38. Soriano, C. et al. (2017). Low-dose aspirin and risk of intracranial bleeds: an observational study in UK general practice. Neurology. 89(22): 2280-2287.
39. Drew, D., Cao, Y. & Chan, A. (2016). Aspirin and colorectal cancer: the promise of precision chemoprevention. Nature Reviews Cancer. 16: 173-186.
40. Kowalski, M. et al. (2018). Diagnosis and management of NSAID-exacerbated respiratory disease – a EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology. 74(1): 28-39.
41. Weiner, D. (2018). Reye syndrome. Medscape Drugs & Diseases. Accessed March 2019. https://emedicine.medscape.com/article/803683-overview#a1
42. Moynihan, B. et al. (2000). Coverage by the news media of the benefits and risks of medications. New England Journal of Medicine. 342: 1645-1650.
43. Robinson, C. et al. (2018). Media reporting of health interventions in New Zealand: a retrospective analysis. Internal Medicine Journal. 48(8): 924-930.
44. Hakim, A. (2011). Perception of risk and benefit in patient-centered communication and care. Patient Intelligence. 3: 39-48.